索拉非尼联合或不联合同期经动脉化疗栓塞治疗晚期肝细胞癌患者:III期STAH试验
BACKGROUND & AIMS: Sorafenib is first-line standard of care for patients with advanced hepatocellular carcinoma (HCC), yet it confers limited survival benefit.…
要点
- 索拉非尼联合cTACE未改善晚期肝细胞癌患者的总生存期(12.8 vs 10.8个月,HR 0.91,p=0.290)。
- 联合组至进展时间(5.3 vs 3.5个月)、无进展生存期(5.2 vs 3.6个月)和肿瘤缓解率(60.6% vs 47.3%)均显著优于单药组。
- 联合组严重(≥3级)不良事件发生率高于单药组(33.3% vs 19.8%,p=0.006)。
核心结论
- 与索拉非尼单药相比,索拉非尼联合cTACE未改善晚期肝细胞癌患者的总生存期,索拉非尼单药仍是晚期肝细胞癌的一线标准治疗。
- 索拉非尼联合cTACE显著改善了至进展时间、无进展生存期和肿瘤缓解率。
研究设计与样本
- 研究者发起的多中心III期试验,患者随机接受索拉非尼单药(S组,n=169)或索拉非尼联合按需cTACE(C组,n=170)。
- 索拉非尼在随机化后3天内开始,cTACE在随机化后7-21天内进行,主要终点为总生存期。
主要发现
- C组与S组中位总生存期12.8 vs 10.8个月(HR 0.91;90%CI 0.69-1.21;p=0.290)。
- C组与S组中位至进展时间5.3 vs 3.5个月(HR 0.67;90%CI 0.53-0.85;p=0.003)。
- C组与S组中位无进展生存期5.2 vs 3.6个月(HR 0.73;90%CI 0.59-0.91;p=0.01)。
- C组与S组肿瘤缓解率60.6% vs 47.3%(p=0.005)。
- C组与S组严重(≥3级)不良事件发生率33.3% vs 19.8%(p=0.006),包括丙氨酸氨基转移酶升高(20.3% vs 3.6%)、高胆红素血症(11.8% vs 3.0%)、腹水(11.8% vs 4.2%)、血小板减少(7.2% vs 1.2%)、厌食(7.2% vs 1.2%)和手足皮肤反应(10.5% vs 11.4%)。
临床怎么用
- 索拉非尼单药仍是晚期肝细胞癌患者的一线标准治疗。
- 对于晚期肝细胞癌需索拉非尼治疗的患者,联合cTACE未改善总生存期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sorafenib is first-line standard of care for patients with advanced hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed to compare clinical outcomes of sorafenib combined with concurrent conventional transarterial chemoembolization (cTACE) vs. sorafenib alone in patients with advanced HCC. METHODS: In this investigator-initiated, multicenter, phase III trial, patients were randomized to receive sorafenib alone (Arm S, n = 169) or in combination with cTACE on demand (Arm C, n = 170). Sorafenib was started within 3 days and cTACE within 7-21 days of randomization. The primary endpoint was overall survival (OS). RESULTS: For Arms C and S, the median OS was 12.8 vs. 10.8 months (hazard ratio [HR] 0.91; 90% CI 0.69-1.21; p = 0.290); median time to progression, 5.3 vs. 3.5 months (HR 0.67; 90% CI 0.53-0.85; p = 0.003); median progression-free survival, 5.2 vs. 3.6 months (HR 0.73; 90% CI 0.59-0.91; p = 0.01); and tumor response rate, 60.6% vs. 47.3% (p = 0.005). For Arms C and S, serious (grade ≥3) adverse events occurred in 33.3% vs. 19.8% (p = 0.006) of patients and included increased alanine aminotransferase levels (20.3% vs. 3.6%), hyperbilirubinemia (11.8% vs. 3.0%), ascites (11.8% vs. 4.2%), thrombocytopenia (7.2% vs. 1.2%), anorexia (7.2% vs. 1.2%), and hand-foot skin reaction (10.5% vs. 11.4%). A post hoc subgroup analysis compared OS in Arm C patients (46.4%) receiving ≥2 cTACE sessions to Arm S patients (18.6 vs. 10.8 months; HR 0.58; 95% CI 0.40-0.82; p = 0.006). CONCLUSION: Compared with sorafenib alone, sorafenib combined with cTACE did not improve OS in patients with advanced HCC. However, sorafenib combined with cTACE significantly improved time to progression, progression-free survival, and tumor response rate. Sorafenib alone remains the first-line standard of care for patients with advanced HCC. LAY SUMMARY: For patients with advanced hepatocellular carcinoma requiring sorafenib therapy, co-administration with conventional transarterial chemoembolization did not improve overall survival compared to sorafenib alone. Therefore, sorafenib alone remains the first-line standard of care for patients with advanced hepatocellular carcinoma. Clinical Trial Number: NCT01829035.
引用
- Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2018. PMID: 30529387. doi:10.1016/j.jhep.2018.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。